EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas

https://doi.org/10.1016/j.cell.2023.03.013 21st June 2021

Article highlights

As we age, our tissues are repeatedly challenged by mutational insult, yet cancer occurrence is a relatively rare event. Cells carrying cancer-causing genetic mutations compete with normal neighbors for space and survival in tissues. However, the mechanisms underlying mutant-normal competition in adult tissues and the relevance of this process to cancer remain incompletely understood. Here, we investigate how the adult pancreas maintains tissue health in vivo following sporadic expression of oncogenic Kras (KrasG12D), the key driver mutation in human pancreatic cancer. We find that when present in tissues in low numbers, KrasG12D mutant cells are outcompeted and cleared from exocrine and endocrine compartments in vivo. Using quantitative 3D tissue imaging, we show that before being cleared, KrasG12D cells lose cell volume, pack into round clusters, and E-cadherin-based cell-cell adhesions decrease at boundaries with normal neighbors.

We identify EphA2 receptor as an essential signal in the clearance of KrasG12D cells from exocrine and endocrine tissues in vivo. In the absence of functional EphA2, KrasG12D cells do not alter cell volume or shape, E-cadherin-based cell-cell adhesions increase and KrasG12D cells are retained in tissues. The retention of KRasG12D cells leads to the early appearance of premalignant pancreatic intraepithelial neoplasia (PanINs) in tissues. Our data show that adult pancreas tissues remodel to clear KrasG12D cells and maintain tissue health. This study provides evidence to support a conserved functional role of EphA2 in Ras-driven cell competition in epithelial tissues and suggests that EphA2 is a novel tumor suppressor in pancreatic cancer.

Group leader

Research topics & keywords

Meet the Research Team

The Cancer Origins group is dedicated to understanding how cancer begins, specifically, how oncogenic cells overcome normal tissue restraints, gain malignant potential, and initiate tumour formation. We are interested in how environmental exposures, such as air pollutants, shape the tissue microenvironment to support the expansion of latent oncogenic cells and promote lung cancer

Photograph of Dr William Hill
William Hill

Group Leader

All publications

Filter by group
Filter by group leader
Filter by research topic
Filter by year
Search publications

https://doi.org/10.1016/j.ccell.2025.04.001

Stromal lipid species dictate melanoma metastasis and tropism

24 April 2025

Institute Authors (5)

Amaya Viros, Duncan Smith, Garry Ashton, Alex Baker, Tim Somervaille

Labs & Facilities

Biological Mass Spectrometry, Histology, Visualisation, Irradiation and Analysis

array(3) { [0]=> int(3758) [1]=> int(3150) [2]=> int(3154) }

Research Group

Skin Cancer & Ageing

array(1) { [0]=> int(2344) }

https://doi.org/10.1038/s41467-025-58343-y

A human model to deconvolve genotype-phenotype causations in lung squamous cell carcinoma

4 April 2025

Institute Authors (4)

Carlos Lopez-Garcia, Robert Sellers, Sudhakar Sahoo, Caroline Dive

Labs & Facilities

Computational Biology Support

array(1) { [0]=> int(3839) }

Research Group

Translational Lung Cancer Biology

array(1) { [0]=> int(2321) }

https://doi.org/10.1186/s12943-024-02157-x

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer

12 November 2024

Institute Authors (1)

Amaya Viros

Labs & Facilities

Genome Editing and Mouse Models

array(1) { [0]=> int(2947) }

Research Group

Skin Cancer & Ageing

array(1) { [0]=> int(2344) }

https://doi.org/10.1186/s13045-024-01610-0

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency

8 October 2024

Institute Authors (6)

Georges Lacaud, Mathew Sheridan, Michael Lie-a-ling, Liam Clayfield, Jessica Whittle, Jingru Xu

Research Group

Stem Cell Biology

int(2449)

/wp-content/uploads/2024/11/Annual-Report-2023.pdf

2023 Annual Report

13 September 2024

https://doi.org/10.1126/science.adh7954

Vitamin D regulates microbiome-dependent cancer immunity

25 April 2024

Institute Authors (3)

Evangelos Giampazolias, Maria Koufaki, Santiago Zelenay

Research Group

Cancer Immunosurveillance

array(1) { [0]=> int(2341) }
Gloved hands filling a stripette white lab coat

Latest from CRUK MI

Cancer Research In the Paterson Building

Find out more about the facilities across the Institute

Leukaemia Immunology & Transplantation

The Leukaemia Immunology and Transplantation laboratory aim to develop a comprehensive strategy to prevent post-transplant relapse in patients treated with allogeneic haematopoietic stem cell transplantation – the only curative therapy for many patients with acute myeloid leukaemia (AML) and other poor-risk haematological malignancies.

Patient derived preclinical models reveal novel biology of SCLC

Immune detection of dying tumour cells can elicit cancer immunity when the host permits it

Cancer Research In the Paterson Building
Leukaemia Immunology & Transplantation
Patient derived preclinical models reveal novel biology of SCLC

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Institute life in Manchester

We strive to make our community a welcoming, caring and enthusiastic one, fuelling ambition with opportunities for training and mentoring to help us all achieve our personal and professional goals.

“We are so pleased to have received the funding to enable us to test our hypothesis in the lab. If we can create a new medicine that can precisely target a specific type of cell within the tumour, and restore anti-cancer immune responses, this will be a game-changer for oesophageal cancer patients “

Sara Valpione

Former Institute Clinical Fellow and now Clinician in Residence within the CRUK National Biomarker Centre

“My charity bake sales – known as “David’s Great British Bake Off” – are always a hit, home baked products taste so much better than shop bought and are greatly appreciated by staff!”

David Jenkins

Purchasing Officer

“We’ve seen some remarkable responses, with an improvement for some patients within days. This is an early phase trial so there’s a lot more work to do. But the data we have so far is very encouraging and could help many thousands of people in the future”

Tim Somervaille

Senior Group Leader

“It is a pleasure to introduce my team who work to deliver our research goals. We work in a friendly and collaborative environment, supporting each other’s projects.  “

Amaya Virós

CRUK Advanced Clinician Scientist Fellow